NCCN Guidelines for Patients® | Myeloproliferative Neoplasms

22 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms, 2018 Part 3 is a treatment guide for essential thrombocythemia (ET, for short). It starts with describing how ET is found. Part 3 also explains the treatment process and options. Your doctor may suggest other options based on your health and wishes. Fully discuss your options with your doctor. Diagnosis ET is commonly found after a blood test that was given for another reason. It is also found due to related symptoms or health events. Common symptoms of ET are fatigue, headaches, dizziness, or vision changes. ET can cause serious health problems. Such problems include blood clots (thrombosis), abnormal bleeding (hemorrhage), and miscarriage during pregnancy. ET is diagnosed based on certain standards. Your platelet count must remain very high over time. Your bone marrow must contain many abnormal platelet-forming cells (megakaryocytes). See Figure 7 . Other types of MPN, MDS, and other myeloid neoplasms must be excluded. There must be no secondary cause for the high platelet counts. Last, usually there is a common mutation like JAK2 , CALR , or MPL mutations. 3 Essential thrombocythemia Diagnosis Figure 7 Key ET Features A diagnosis of ET requires high numbers of megakaryocytes and platelets. A megakaryocyte is a rare type of bone marrow cell. When mature, it extends its arms through the wall of a blood vessel and releases platelets into the bloodstream. Copyright © 2017 National Comprehensive Cancer Network ® (NCCN ® ). megakaryocyte platelets Routine blood work showed high platelets and a following bone marrow biopsy confirmed the ET diagnosis. – Lyn Survivor, Essential thrombocythemia “